
08/07/2025
This 3-year, multi-registry study will assess real-world use of abrocitinib vs conventional systemic therapies in atopic dermatitis across 5 European registers. Read more here: https://doi.org/10.1093/skinhd/vzaf020
Skin Health and Disease is a multidisciplinary international open-access journal covering all aspect
London
Be the first to know and let us send you an email when Skin Health and Disease posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Send a message to Skin Health and Disease: